- Home
- TNGX vs WINA Comparison
TNGX vs WINA Comparison
Compare TNGX & WINA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | WINA |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | TNGX | WINA |
|---|---|---|
| Price | $12.66 | $432.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 87.9K |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 2.58% |
| EPS Growth | N/A | ★ 2.56 |
| EPS | N/A | ★ 11.21 |
| Revenue | $66,501,000.00 | ★ $84,517,400.00 |
| Revenue This Year | $52.80 | $7.05 |
| Revenue Next Year | N/A | $3.60 |
| P/E Ratio | ★ N/A | $39.28 |
| Revenue Growth | ★ 53.29 | 3.35 |
| 52 Week Low | $1.03 | $295.79 |
| 52 Week High | $13.18 | $527.37 |
Technical Indicators
Market Signals| Indicator | TNGX | WINA |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 53.27 |
| Support Level | $11.33 | $404.76 |
| Resistance Level | $11.85 | $459.99 |
| Average True Range (ATR) | 1.10 | 19.77 |
| MACD | 0.31 | 2.29 |
| Stochastic Oscillator | 83.93 | 57.43 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.